Zobrazeno 1 - 10
of 45
pro vyhledávání: '"R. S. Porter"'
Publikováno v:
Anaesthesia. 69(4)
Publikováno v:
Anaesthesia. 68(4)
Recently, increasing attention has been drawn to haemophagocytic lymphohistiocytosis as a potentially under-diagnosed condition in critically ill patients with severe sepsis. It is thought to be caused by a highly stimulated, but ineffective, immune
Autor:
R. S. Porter, K. T. Schell
Publikováno v:
Molecular Crystals and Liquid Crystals. 182:185-194
The phase behavior for three binary liquid crystalline systems has been explored. All three contained the room-temperature nematic, 4-4'-n-pentylcyanobiphenyl (K15), as one of their components. K15 has a T KN of 22.3 o C and a T NI of 35.1 o C. The s
Autor:
Sornchai Looareesuwan, Frank Hills, David A. Warrell, L Sjöström, Polrat Wilairatana, R S Porter, Srivicha Krudsood
Publikováno v:
The American journal of tropical medicine and hygiene. 61(1)
Single doses (250, 500, 1,000, or 2,000 units/kg) of an ovine polyclonal-specific Fab fragment directed against tumor necrosis factor-alpha (TNF-alpha) were given to 17 adult patients with severe falciparum malaria immediately before treatment with a
Autor:
R. S. Porter
Publikováno v:
JAMA: The Journal of the American Medical Association. 287:984-985
Publikováno v:
Clinical cardiology. 15(1)
Dosage of encainide for patients with lethal ventricular arrhythmias is based on pharmacodynamic effects and efficacy of arrhythmia suppression, coupled with metabolizer phenotype and extent of renal and hepatic dysfunction. Decreased clearance in pa
Publikováno v:
American journal of preventive medicine. 7(6)
Researchers disagree about the extent to which limited access to health services negatively affects health. In this study, we investigated the association of health status with access to high blood pressure medication among hypertensive respondents d
Autor:
R S, Porter, J R, Dipalma
Publikováno v:
American family physician. 44(4)
More than 10 years ago, thrombolytic therapy with urokinase and streptokinase for pulmonary embolism was found to have considerable advantages over standard heparin therapy. After the introduction of alteplase, a recombinant tissue plasminogen activa
Autor:
R S, Porter, J R, DiPalma
Publikováno v:
American family physician. 44(2)
Three agents approved for the lysis of thrombi in coronary arteries--alteplase, anistreplase and streptokinase--have undergone critical clinical experimental trials in Europe and the United States. Global comparison of their efficacy shows that altep
Autor:
R S, Porter
Publikováno v:
Clinical pharmacy. 9(4)